Detection of low-level EGFR T790M mutation in lung cancer tissues (Q39531710)

12 September 2017

title

Detection of low-level EGFR T790M mutation in lung cancer tissues (English)

1 reference

12 September 2017

1 reference

Ji Eun Oh

1

1 reference

12 September 2017

Chang Hyeok An

series ordinal

2

1 reference

12 September 2017

Nam Jin Yoo

series ordinal

3

1 reference

12 September 2017

Sug Hyung Lee

series ordinal

4

1 reference

12 September 2017

publication date

14 May 2011

1 reference

Acta Pathologica et Microbiologica Scandinavica

12 September 2017

published in

1 reference

12 September 2017

volume

119

1 reference

12 September 2017

issue

7

1 reference

12 September 2017

page(s)

403-411

1 reference

Epidermal growth factor receptor: mechanisms of activation and signalling.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02738.X

10.1111/J.1600-0463.2011.02738.X

21 January 2018

Identifiers

DOI

1 reference

release_ccatk5s5h5cm7khydqjgxag6la

12 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ccatk5s5h5cm7khydqjgxag6la

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference